News

VIPC Awards Commonwealth Commercialization Fund Grant to Carilion Medical Center

Carilion Medical Center is a non-profit healthcare organization based in Roanoke, Va. The principal investigator for this grant is Dr. Umar Sofi, MD, is a practicing pulmonologist and an Associate Professor of Medicine at the Virginia Tech Carilion School of Medicine in Roanoke, Va. The CCF-funded project grew from Dr. Sofi’s frustration with currently available oxygen delivery systems, which are time-consuming for healthcare providers and do not respond to a patient’s ever-changing oxygen needs. In response to this need, Dr. Sofi assembled a cross-functional team of experts from Carilion Clinic and Virginia Polytechnic Institute and State University (Virginia Tech) to design and build an innovative oxygen delivery system. The flow-regulated nasal oxygen delivery system (FRNDS) offers significant improvements compared to legacy oxygen delivery systems.

“We appreciate the CCF grant from VIPC for FRNDS,” said Dr. Umar Sofi. “There is currently no device for high-flow oxygen that can adapt to a patient’s respiratory needs. We are developing FRNDS to overcome those hurdles by measuring a patient’s inspiratory flow to improve patient outcomes.”

“We are pleased to award a CCF grant to support Dr. Sofi’s commercialization efforts,” said Hina Mehta, PhD, VIPC’s Director for University Programs. “VIPC’s CCF higher education grant program plays an important role in getting funding to Virginia’s entrepreneurially-minded university researchers as they work to take innovations from lab to market. Dr. Sofi’s research has identified a significant unmet need in the respiratory care field, and he is leading a top-notch team that is committed to building and demonstrating a working prototype of FRNDS.”

CCF accepts applications and awards funding on a rolling basis to Virginia’s small businesses and university-based innovators. The CCF Higher education grant program seeks to fund high-potential Virginia-based academic research teams that are developing technologies with strong commercial potential. The grants support early technology and market validation efforts such as customer discovery, market research, business model validation, development of prototypes or a minimum viable product (MVP), customer pilots, intellectual property protection, team development, and more. For more information on funding opportunities and eligibility requirements, or to apply, visit: www.VirginiaIPC.org

Recent News

07/15/2026

Focused Ultrasound Foundation Chairman Receives Lifetime Impact Award

Neal F. Kassell, MD, founder and chairman of the Focused Ultrasound Foundation, received the inaugural Lifetime Impact Award at the 2026 annual meeting of the International Society for Therapeutic Ultrasound (ISTU) in Norway in June. The award honors individuals whose work has fundamentally shaped the development, adoption, and global impact of focused ultrasound. “Dr. Kassell’s

07/14/2026

ARPA-H awards up to $160 million to advance personalized curative medicines for rare genetic diseases

The Advanced Research Projects Agency for Health (ARPA-H), an agency within the U.S. Department of Health and Human Services, today announced the teams for the Treating Hereditary Rare Diseases with In Vivo Precision Genetic Medicines (THRIVE) program — a critical investment toward bringing new treatments to patients faster and cure rare genetic pediatric diseases. THRIVE

07/09/2026

Quoin Pharmaceuticals Receives FDA IND Clearance to Initiate Phase 2 Study of QRX003 in Peeling Skin Syndrome

Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX), a late clinical-stage specialty pharmaceutical company focused on rare and orphan diseases, announced that the U.S. Food and Drug Administration (FDA) has cleared the Company’s Investigational New Drug (IND) application for QRX003 for the treatment of Peeling Skin Syndrome (PSS), enabling initiation of its planned Phase 2 clinical study. Quoin